Genmab — Maj 2020

[kkjoel]

Så iflg. JNJ er Amivantamab i PhII og både Teclistamab (7957) og Talquetamab (7564) er "potentielle/planlagte" filings inden 2023.

[kkjoel]

Alle 3 potentielle BBs og med min. 10% på hver... what's not to like?

[kkjoel]

Synes Jan skal køre videre i al uendelighed uden udbytte (à la Buffett) - bare sørge for at værdien vokser med de der 10-15-20% /år

[Bulder]

Kan huske vi for år tilbage snakkede om, at det ville være rart at få valideret duobody-teknologien. Det må da siges at være opnået nu.

[Helge_LarsenPI-redaktør]

Enig Bulder.

[GeorgeBest]

Får Genmab også 10% på Teclistamab og Talquetamab? Der er vel kun dobbel digit hvis begge ben i duobodien er udviklet af Genmab (som Amivantamab).

[E_L]

"The royalty percentage varies from single digits to double digits and is different between the various programs…"

[GeorgeBest]

yes but I beleive
royalties are higher if both legs in the duo are developed by Genmab...

[E_L]

We know that pre-treatment with dara was found to enhance the efficacy of JNJ-957; the combination Tecli-DaraFaspro would improve the royalties

[GeorgeBest]

ofcourse

[E_L]

@10.57 that is only the case for amivantamab as far as i am aware

[GeorgeBest]

yes I agree

[Sukkeralf]

It could be an interesting question on next Q&A - if Jan could reveal any Genmab delivered arms to Janssens Duobodies. I guess its a no but you never no !

[Sukkeralf]

no = know

[Sukkeralf]

Since Genmab for a long time have been very interested in the CDC mechanism of antibodies with this focus on ofatumumab compared to rituximab. And off cause with the hexabody technology I wonder why they havent focussed on IgM antibodies ?

[Sukkeralf]

They are much more complex so maybe they have tried. Otherwise I would love to see them do a partnership with IGM Bioscience - it could be on their DR5/DR5 IGM antibody if Genmabs DR5/DR5 hexabody fails.

[Sukkeralf]

FC(F)(P(=O)(OCC)OCC)c2cc1c([nH]c(c1)C(=O)O)cc2

[E_L]

@11.17 i see no reaseon for him not to answer, for amivantamab it is explicitly stated on their website https://www.genmab.com/product-pipeline/products-in-development/amivantamab

[bibob]

Medicinrådet siger nej til Darzalex udfordrer fra BMS https://medwatch.dk/Medicinal___Biotek/article12152125.ece

[Sukkeralf]

Normally Jan likes to show off a bit - so when he dont itse probably because he cant ! He could say something without being specific